News | Artificial Intelligence | December 05, 2018

Fujifilm Collaborates With Lunit on AI Pilot Project

Collaboration will integrate Lunit Insight with Fujifilm’s REiLI AI platform across 94 clinics in Mexico

Fujifilm Collaborates With Lunit on AI Pilot Project

December 5, 2018 —  Fujifilm Medical Systems USA Inc. announced a joint collaboration with Korean-based medical artificial intelligence (AI) company Lunit Inc. and Salud Digna, one of the largest diagnostic service providers in Mexico with 94 clinics around 24 states. The goal of the collaboration is to have radiologists in a real-world setting evaluate AI technologies for diagnostic imaging being developed by both Fujifilm and Lunit.

Under the pilot project, Fujifilm's REiLI AI platform within Fujifilm's Synapse 5 PACS (picture archiving and communication system) will be integrated with Lunit Insight, Lunit's medical AI solution for chest radiography and mammography, at multiple Salud Digna facilities. The objective of the pilot project is to obtain feedback and input from approximately 20 radiologists at Salud Digna, with the long-term goal of advancing the development of AI applications and technologies of both Fujifilm and Lunit. The project also seeks to evaluate worklist prioritization features based on AI solution results that are in development within Synapse 5 PACS. These features are intended to improve radiologists' productivity as well as the speed and accuracy of diagnosis.

Under the REiLI brand, Fujifilm is developing AI technologies that support diagnostic imaging, medical workflow, and equipment warranty and service by leveraging deep learning with Fujifilm's image processing. In an increasingly complex healthcare environment with massive datasets and rising demand for high-quality care, AI technology has the potential to change the practice of medicine, according to the company.

For more information: www.fujimed.com

Related Content

icobrain cva allows the quantitative assessment of tissue perfusion by reporting the volume of core and perfusion lesion by quantifying Tmax abnormality and CBF abnormality together with the mismatch volume and ratio
News | Artificial Intelligence | February 23, 2021
February 23, 2021 — icometrix, world leader in imaging...
Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in

Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in (a). The bottom row focuses on the detection of small calcifications, a key feature in DCIS. These are undetectable in (d), detected in (e), enhanced in the maximum intensity projection (MIP) image at the bottom of (f), and confirmed by histopathology in the top part of (f). The scale bar [shown in (b) and (e)] is the same for all images apart from (f), which has its own scale. Red arrows in (e) and (f) indicate the microcalcifications. Image courtesy of Professor Alessandro Olivo

News | Breast Imaging | February 22, 2021
February 22, 2021 — A new X-ray imaging scanne
F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

News | Molecular Imaging | February 22, 2021
February 22, 2021 — Molecular imaging
GE Healthcare introduced its artificial intelligence (AI) automation features on its Voluson Swift ultrasound platform at the 2020 Radiological Society of North America (RSNA) virtual meeting. Features of this system include semi-automated contouring, auto identification of fetal anatomy and positioning on imaging. AI is seeing increasing integration in ultrasound systems from numerous vendors.

GE Healthcare introduced its artificial intelligence (AI) automation features on its Voluson Swift ultrasound platform at the 2020 Radiological Society of North America (RSNA) virtual meeting. Features of this system include semi-automated contouring, auto identification of fetal anatomy and positioning on imaging. AI is seeing increasing integration in ultrasound systems from numerous vendors.

Feature | Ultrasound Imaging | February 18, 2021 | By Dave Fornell, Editor
Recent advances in ultrasound image sy...
Example MR images from paediatric brain tumour patients. This first column shows T1-weighted images following the injection of gadolinium contrast agent. The second column shows T2-weighted images and the final column shows apparent diffusion coefficient maps calculated from diffusion-weighted images. (a–c) are taken from a patient with a Pilocytic Astrocytoma, (d–f) are from a patient with an Ependymoma and (g–i) were acquired from a patient with a Medulloblastoma.

Example MR images from paediatric brain tumour patients. This first column shows T1-weighted images following the injection of gadolinium contrast agent. The second column shows T2-weighted images and the final column shows apparent diffusion coefficient maps calculated from diffusion-weighted images. (ac) are taken from a patient with a Pilocytic Astrocytoma, (df) are from a patient with an Ependymoma and (gi) were acquired from a patient with a Medulloblastoma. Image courtesy of Nature Research Journal

News | Pediatric Imaging | February 17, 2021
February 17, 2021 — Diffusio...
A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms.

A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms. Images from Christiane Kuhl, M.D.

Feature | MRI Breast | February 17, 2021 | By Dave Fornell, Editor
Dense breast tissue can hide cancers i
Radiology, radiation therapy, PACS, Enterprise image, X-ray, DR Systems, CT, MRI, contrast, ultrasound, VNA, product comparisons, comparison charts on ITN magazine.
Feature | February 17, 2021
Imaging Technology News (ITN) maintains more than 40
Brazilian researchers found that the higher the lung ultrasound score the greater the risk of ICU admission, intubation and death. Image courtesy of Julio Alencar

Brazilian researchers found that the higher the lung ultrasound score the greater the risk of ICU admission, intubation and death. Image courtesy of Julio Alencar

News | Coronavirus (COVID-19) | February 11, 2021
February 11, 2021 — ...
The research collaboration agreement covers a joint clinical retrospective study on liver fibrosis severity in Non-Alcoholic Steato-Hepatitis (NASH) patients
News | Artificial Intelligence | February 10, 2021
February 10, 2021 — Median Technologies announced the company has signed a research collaboration agreement with the